Category Archives: ceritinib – Zykadia from Novartis

Article on latest develpments

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Long term phase 1 data for Ceritinib

On March 10 an article was published on the long term results of a phase 1 trial of Ceritinib. The trial enrolled 255 patients from January 2011 and July 2013 of whom 246 had ALK + lung cancer. Data cutoff … Continue reading

Posted in Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Research, Resistance to treatment, Side Effects | Leave a comment

Article by Dr. Shaw

Dr. Shaw discusses the recent approval of Alectinib and the treatment implications now that there are 3 ALK inhibitors approved by the FDA. http://www.ascopost.com/issues/january-25-2016/the-evolving-treatment-landscape-of-alk-positive-nsclc/

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Imunotherapies, Lung cancer, Potential Treatments, Research | Leave a comment

Editorial on Brain mets and ALK lung cancer

The Journal of Clinical Oncology has an editorial about the current research on treating brain mets for ALK+ patients that discusses ALK inhibitors and different kinds of radiation treatments. Treatments discussed include: 1) Crizotinib, 2) Ceritinib 3) Alectinib 4) brigatinib, … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

Survey of ALK inhibitors effects on brain mets

This survey summarizes the results of other research to describe the current level of knowledge about how effective different ALK inhibitors are at treating brain mets. Inhibitors that are discussed include crizotinib, ceritinib, alectinib, AP26113 (brigatinib) and PF-06463922 (lorlatinib). http://www.thecco.net/article/view/6520/7543

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Comparison of 3 ALK inhibitors’ phase 2 trials

All of these results are based on 5 phase 2 trials. However the conditions of each trial may differ in important ways. For example, it is my understanding that the trial for brigatinib was limited to healthier patients while the … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

3 Ceritinib abstracts

Abstracts 8060, 8059, and 8058 relate to Ceritinib. Please see glossary for acronym definitions. Abstract 8060 covers the Ascend 3 trial, which is a phase 2 trial that includes ALK inhibitor naive patients. As of 6-27-2014 the trial had 124 … Continue reading

Posted in Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

ASCO links

Here are 18 ALK+ related abstract links related to the drugs listed below. On the ASCO website 77 abstracts refered to both “ALK” and “Inhibitor”.  When I get a chance I will write up a summary on some of the … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro | Leave a comment

Novartis update

On May 8, 2015 Novartis announced that Zykadia (ceritinib) was approved by the European Commission to treat ALK+ lung cancer patients previously treated with Crizotinib.

Posted in ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer | Leave a comment

Effectivness of certain 2nd generation ALK inhibitors against specific ALK mutations

Four 2nd generation ALK inhibitors (Ceritinib, Alectinib, AP26113, and ASP3026) were tested in vitro against six known mutations of the ALK fusion gene. Generally, AP26113 (brigatinib) was most effective and ASP3026 was least effective. In some cases one drug worked … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, ceritinib - Zykadia from Novartis, Lung cancer, Research, Resistance to treatment | Leave a comment